Brind.

Galleri is the multi-cancer early detection test developed by GRAIL.

1 report, 1 independent Updated Jul 14

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

GRAIL

Keep exploring

The entities involved

GRAIL
American biotechnology and pharmaceutical company
- TD Cowen provided a buy rating on GRAIL shares on August 6, 2026.Fri 07:06

Related events

The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.Jun 22
FDA voted in favor of the safety and effectiveness of GRAIL's Galleri blood test.Oct 11

Coverage

Newest first; wire copies grouped

Jul 14Insider MonkeyGRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission GRAIL Inc. (NASDAQ:GRAL) is one of the best young stocks to buy and hold for 5 years. On